Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 84

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 8
Chunk 84
---
5,904 Revenue from intangible royalty assets40,161 26,552 91,832 67,512 Qarziba5,976 4,628 17,303 4,628 Other449 529 1,337 1,826 Income from financial royalty assets6,425 5,157 18,640 6,454 Total royalties46,586 31,709 110,472 73,966 Captisol10,672 6,255 32,419 22,967 Contract revenue and other incomeIncome from Pelthos Transaction53,072 — 53,072 — Contract revenue131 13,848 6,441 25,444 Other income5,000 — 6,017 1,944 Contract revenue and other income58,203 13,848 65,530 27,388 Total$115,461 $51,812 $208,421 $124,321 Short-term InvestmentsOur short-term investments consist of the following at September 30, 2025 and December 31, 2024 (in thousands):September 30, 2025Amortized costGross unrealized gainsGross unrealized lossesEstimated fair value     Corporate notes/bonds$134,162 $71 $(91)$134,142      U.S. Treasuries121,248 61 (18)121,291      Commercial paper118,371 30 (29)118,372      U.S. Government Agencies98,714 56 (34)98,736      Corporate equity securities15,056 36,686 (3,657)48,085      Certificates of Deposit4,520 — — 4,520 Total short-term investments$492,071 $36,904 $(3,829)$525,146 December 31, 2024     U.S. Treasuries$78,442 $19 $(13)$78,448      Corporate equity securities11,386 38,808 (6,595)43,599      Commercial paper23,483 5 (6)23,482      Certificates of Deposit22,812 12 (4)22,820      Corporate notes/bonds15,496 21 (8)15